Bionano Genomics Inc (BNGO) - Total Liabilities
Based on the latest financial reports, Bionano Genomics Inc (BNGO) has total liabilities worth $15.98 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check BNGO asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Bionano Genomics Inc - Total Liabilities Trend (2016–2025)
This chart illustrates how Bionano Genomics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Bionano Genomics Inc (BNGO) total assets.
Bionano Genomics Inc Competitors by Total Liabilities
The table below lists competitors of Bionano Genomics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Toleranzia AB
ST:TOL
|
Sweden | Skr9.54 Million |
|
M.P.Evans Group
LSE:MPE
|
UK | GBX60.30 Million |
|
Picard Medical, Inc.
NYSE MKT:PMI
|
USA | $18.76 Million |
|
Encorp Bhd
KLSE:6076
|
Malaysia | RM510.81 Million |
|
ASTORY Co.Ltd
KQ:241840
|
Korea | ₩10.09 Billion |
|
CNPLUS Co. Ltd.
KQ:115530
|
Korea | ₩47.39 Billion |
|
Antec Inc
TWO:6276
|
Taiwan | NT$380.09 Million |
|
Vakif Menkul Kiymet Yatirim Ortakligi AS
IS:VKFYO
|
Turkey | TL2.05 Million |
Liability Composition Analysis (2016–2025)
This chart breaks down Bionano Genomics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See BNGO equity to assets ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.48 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.51 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.34 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bionano Genomics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bionano Genomics Inc (2016–2025)
The table below shows the annual total liabilities of Bionano Genomics Inc from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $29.16 Million | -29.39% |
| 2024-12-31 | $41.30 Million | -65.08% |
| 2023-12-31 | $118.25 Million | +103.51% |
| 2022-12-31 | $58.10 Million | +45.33% |
| 2021-12-31 | $39.98 Million | +57.61% |
| 2020-12-31 | $25.37 Million | -4.61% |
| 2019-12-31 | $26.59 Million | +81.34% |
| 2018-12-31 | $14.67 Million | -75.71% |
| 2017-12-31 | $60.37 Million | +43.58% |
| 2016-12-31 | $42.05 Million | -- |
About Bionano Genomics Inc
Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simpl… Read more